Clinical trials
Inflammatory Myositis clinical trials
Below are recruiting inflammatory myositis clinical trials, each written for real people, not researchers. We’re tracking 16 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05454527Recruiting
Biobank study follow-up for adults with inflammatory muscle disease
This study follows adults who have (or are being evaluated for) inflammatory muscle conditions to collect health data and genetic test information. It may help researchers better understand these diseases and improve future care.
ParisAges 18 years+ - NCT05979441Enrolling by invitationPhase 3
Long-term safety of efgartigimod injection for myositis
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
Phoenix, ArizonaAges 18 years+ - NCT07160205RecruitingPhase 2/Phase 3
Study of ULSC for dermatomyositis and polymyositis
This trial tests a new treatment called ULSC to see if it can improve muscle strength and skin symptoms, and help reduce steroid use in people with dermatomyositis or polymyositis. It may be an option if standard treatments haven't worked well enough.
Gainesville, FloridaAges 18 years+ - NCT07374107Recruiting
Patient insights for shaping myositis research
This study asks people with autoimmune muscle diseases (myositis) and their caregivers to share their experiences and insights. By joining, you help shape better research and care for myositis.
New Orleans, LouisianaAges 7 years+ - NCT06479863RecruitingEarly Phase 1
Testing a new drug combo for inclusion body myositis
This trial tests a combination of two investigational drugs (pozelimab and cemdisiran) to see if they can help people with sporadic inclusion body myositis, a muscle disease that causes progressive weakness. If the drugs work, they may slow down the disease and help you stay stronger longer.
Austin, TexasAges 45–75 - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Beverly Hills, CaliforniaAges 12–70 - NCT06593041Recruiting
Platelets in lupus and other autoimmune diseases
This study looks at how platelets (small blood cells that help with clotting) might play a role in autoimmune diseases like lupus. By understanding this, researchers hope to find new ways to treat these conditions.
Strasbourg, FranceAges 18–70 - NCT06642870Recruiting
Self-management programme for rare rheumatic conditions
This trial is developing a self-management programme for people with rare rheumatic conditions like lupus, vasculitis, myositis, or Sjogren syndrome. It aims to help participants better manage their condition and improve their quality of life.
BristolAges 18 years+ - NCT05251415Recruiting
Study of rare autoimmune diseases with blood and medical samples
This trial collects clinical and lab information (like blood and medical history) from people with rare autoimmune diseases, especially when symptoms are unusual. It aims to better understand what causes these illnesses and how newer treatments may help.
ToulouseAges 6–99 - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70 - NCT06154252RecruitingPhase 2/Phase 3
Study of CABA-201 for active myositis in adults and children
This trial tests a new treatment called CABA-201, which uses your own immune cells modified to attack the overactive cells causing myositis. It is for people with active disease that hasn't improved enough with standard therapies.
Orange, CaliforniaAges 6–75 - NCT05895786RecruitingPhase 3
Study drug for active dermatomyositis or polymyositis
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
Glendale, ArizonaAges 18 years+ - NCT06991114RecruitingPhase 2
AlloNK and rituximab for relapsing rheumatologic diseases
This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.
Tuscaloosa, AlabamaAges 18 years+ - NCT07478172Recruiting
Electrical muscle stimulation exercise for neuromuscular disease
This study tests whether whole-body electrical muscle stimulation (using small electrodes on the skin) can help adults with certain neuromuscular diseases exercise and improve muscle strength. It may be an option if you can stand for about 15 minutes at a time and have some muscle strength left.
Columbia, MissouriAges 18 years+ - NCT06605612Enrolling by invitation
Falls risk test for people with muscle and nerve conditions
This study is creating a test to predict falls in people with neuromuscular disorders. You will fill out a questionnaire about your fall risk.
München, BavariaAges 18–65 - NCT07072676Enrolling by invitation
Can a walker help prevent falls in neuromuscular disease?
This study tests if using assistive walking devices, after a short training period, can lower the risk of falls in people with neuromuscular diseases. It aims to help you stay steady and safe on your feet.
Bad FeilnbachAges 65–65
Hear when a new Inflammatory Myositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for inflammatory myositis?
- Yes. Clin2 currently lists 16 recruiting inflammatory myositis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a inflammatory myositis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a inflammatory myositis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.